HeyJaredMathini Ilancheran
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Clinicalleader
- Top 5M sites
- Earliest in this view
- Aug 7, 2026
Latest articles
09.17.26 -- Five Ways To Enrich The Clinical Trial Ecosystem (opens the original)
Read excerpt
Could Your CTR Approval Take Just Six Weeks? The EU Clinical Trial Regulation is often perceived as a source of delay. Yet, with early planning, aligned processes and experienced research sites, trial applications can be authorised in as little as six weeks. Discover which factors have the greatest impact on timelines and submission success. Read the article. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing Guest Column | By Mathini Ilancheran, R&D Beroe Inc. Math
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing (opens the original)
Read excerpt
By Mathini Ilancheran, senior delivery lead - research, R&D, Beroe Inc. Editor’s note: This guest column is a follow-up to “U.S. Drug Tariffs: Implications for Pharma and Outsourcing.” On July 21, 2026 President Trump announced that imported generic drugs will remain duty-free for two years from August 1, 2026, then face a 100% tariff from August 2028 and 200% from August 2029, to be implemented under Section 232.1–3 This closes the last gap in a framework that already covers patented medicines,
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing (opens the original)
Read excerpt
By Mathini Ilancheran, senior delivery lead - research, R&D, Beroe Inc. Editor’s note: This guest column is a follow-up to “U.S. Drug Tariffs: Implications for Pharma and Outsourcing.” On July 21, 2026 President Trump announced that imported generic drugs will remain duty-free for two years from August 1, 2026, then face a 100% tariff from August 2028 and 200% from August 2029, to be implemented under Section 232.1–3 This closes the last gap in a framework that already covers patented medicines,
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing (opens the original)
Read excerpt
By Mathini Ilancheran, senior delivery lead - research, R&D, Beroe Inc. Editor’s note: This guest column is a follow-up to “U.S. Drug Tariffs: Implications for Pharma and Outsourcing.” On July 21, 2026 President Trump announced that imported generic drugs will remain duty-free for two years from August 1, 2026, then face a 100% tariff from August 2028 and 200% from August 2029, to be implemented under Section 232.1–3 This closes the last gap in a framework that already covers patented medicines,
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Clinicalleader, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.